0000899243-22-038516.txt : 20221214
0000899243-22-038516.hdr.sgml : 20221214
20221214200027
ACCESSION NUMBER: 0000899243-22-038516
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221212
FILED AS OF DATE: 20221214
DATE AS OF CHANGE: 20221214
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Astle Christopher
CENTRAL INDEX KEY: 0001915257
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41535
FILM NUMBER: 221463442
MAIL ADDRESS:
STREET 1: 114 EAST 4TH AVENUE, SUITE 800
CITY: VANCOUVER
STATE: A1
ZIP: V5T 1G4
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Zymeworks Inc.
CENTRAL INDEX KEY: 0001937653
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 108 PATRIOT DRIVE, SUITE A
CITY: MIDDLETOWN
STATE: DE
ZIP: 19709
BUSINESS PHONE: 206-337-1030
MAIL ADDRESS:
STREET 1: 108 PATRIOT DRIVE, SUITE A
CITY: MIDDLETOWN
STATE: DE
ZIP: 19709
FORMER COMPANY:
FORMER CONFORMED NAME: Zymeworks Delaware Inc.
DATE OF NAME CHANGE: 20220712
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-12-12
0
0001937653
Zymeworks Inc.
ZYME
0001915257
Astle Christopher
C/O ZYMEWORKS INC.
108 PATRIOT DRIVE, SUITE A
MIDDLETOWN
DE
19709
0
1
0
0
SVP & Chief Financial Officer
Common Stock
2022-12-12
4
M
0
1550
0.00
A
2220
D
Common Stock
2022-12-12
4
S
0
887
6.01
D
1333
D
Restricted Stock Unit
2022-12-12
4
M
0
1550
0.00
D
Common Shares
1550
1550
D
Represents shares of common stock issued upon vesting of one half of the restricted stock units ("RSUs") granted on December 10, 2021.
Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs. Pursuant to the terms of the applicable RSU grant agreement (the "Grant Agreement"), effective on the grant date of the RSUs, the Reporting Person adopted a 10b5-1 plan pursuant to which the Reporting Person elected to sell shares to cover tax withholding obligations and other applicable fees in accordance with the terms of the Grant Agreement.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.99 to $6.035, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.
The RSUs were granted on December 10, 2021 and vest in two equal annual instalments beginning on December 12, 2022.
On October 13, 2022, the Issuer (formerly Zymeworks Delaware Inc., a Delaware corporation) became the successor issuer of Zymeworks BC Inc. (formerly Zymeworks Inc., a corporation continued under the Business Corporations Act (British Columbia)) pursuant to Rule 12g-3 of the Securities Exchange Act of 1934, as amended. On such date the Issuer completed a series of transactions, including a redomicile, pursuant to a statutory plan of arrangement under Section 288 of the Business Corporations Act (British Columbia), as a result of which common shares of Zymeworks BC Inc. were exchanged for either shares of common stock of the Issuer or exchangeable shares issued by Zymeworks ExchangeCo Ltd., an indirect subsidiary of the Issuer.
/s/ Daniel Dex, Attorney-in-Fact
2022-12-14